Pfizer has entered into an acquisition agreement with AstraZeneca AB, Sweden (AstraZeneca), pursuant to which the brand ‘Neksium’ is being acquired by the company in India for a consideration of Rs 75 crore, subject to completion of necessary conditions precedent. Neksium (esomeprazole) complements the company’s existing product portfolio in the gastrointestinal (GI) therapeutic area.
Earlier in January, the company had entered into a Delegation of Authority with AstraZeneca Pharma India, pursuant to which AstraZeneca has granted certain authority to the company to conduct certain activities in India.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1470.45 |
Dr. Reddys Lab | 5973.00 |
Cipla | 1547.95 |
Zydus Lifesciences | 1090.00 |
Lupin | 1555.10 |
View more.. |